Antidepressants
Venlafaxine, an SNRI, was the only antidepressant assessed for mood in women after breast cancer. One RCT (with a moderate risk of bias) found no statistically significant difference in effect on mood between venlafaxine (37.5mg/twice per day) and clonidine (0.075mg/twice per day for 4 weeks), but reported that venlafaxine significantly improved mood compared with baseline.23
One RCT (with a moderate risk of bias) found a statistically significant reduction on negative mood for venlafaxine (75mg/d for 21 days) compared with gabapentin (900mg/d for 22 days).24
One RCT (with a moderate risk of bias) found a significant improvement on emotional wellbeing for the SSRI sertraline (25-100mg/d for 4 weeks) compared with placebo,17 while another RCT (with a moderate risk of bias) found no significant difference on emotional wellbeing between the SNRI venlafaxine (37.5mg/d or 75mg/d for 6 weeks) and placebo.21